Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

With its vaccine candidate finally in Phase II, Inovio is bagging $3 million in a partnership deal with Advaccine Biopharmaceuticals Suzhou to develop and commercialize …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Covid-19 roundup: In­ovio nabs $3 mil­lion and a de­vel­op­ment part­ner for its vac­cine that's still on par­tial hold; Slaoui pro­pos­es halv­ing Mod­er­na vac­cine dos­es as dis­tri­b­u­tion lags

Senior Editor

Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags